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Reoperation on prosthetic heart valves 
Patient-specific estimates of in-hospital events 
Reoperation on prosthetic heart valves is increasingly under consideration for both clinical and 
prophylactic ndications. To determine the correlates of hospital events, including in-hospital mortality, 
new persisting neurologic deficit, and length of postoperative stay, a three-institution study of 2246 
consecutive prosthetic valve reoperations performed on 1984 patients between 1963 and 1992 was 
undertaken. The combined experience ranged from high-risk patients coming moribund to the operating 
room to an important number of well individuals undergoing prophylactic reoperations on potentially 
failing valves. The risk-unadjusted hospital mortality was 10.8%, neurologic deficit at hospital discharge 
1.1%, and length of stay 10 days (median). Multivariably determined correlates of outcome included age 
at reoperation, degree, severity, and acuity of impairment of cardiac function, extensiveness of valvular 
heart disease, coexisting morbid conditions, number of previous heart operations, and concomitant 
procedures. The risk-adjusted hospital mortality for the first elective reoperation i a good-risk patient 
was 1.3% (90% confidence limits 0.3% to 4.4%), neurologic deficit 0.3% (90% confidence limits 0.02% to 
1.8%), and length of postoperative stay 7 days (9t)% confidence limits 4 to 13), emphasizing the wide 
variance in outcome vents. Equations were developed to permit wide application of the results of the 
study for quantitatively estimating the risk of outcome vents based on individual preoperative patient 
characteristics. These estimates should be useful for informed patient consent, considerations of pro- 
phylactic valve replacement, and cost and resource use. (J TttORAC CARDIOVASC SURG 1995;109:30-48) 
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Actua l  or threatened prosthetic heart valve dys- 
function ecessitates weighing the risks and benefits of 
reoperation versus retention of the prosthesis. 1 Be- 
cause prosthetic heart valve reoperation is uncommon, 
most single institutions report a small number of 
patients, z-9 which may not adequately represent the 
entire spectrum of patients for whom prosthetic valve 
reoperations might be considered. This is particularly 
true with regard to prophylactic explantation of valve 
prostheses in otherwise well patients. Further, these 
reports do not provide the means for numeric predic- 
tion of operative risk or other events for a given 
patient with a specific constellation of risk factors 
(so-called patient-specific estimates). 
Therefore, three experienced academic centers 
analyzed their combined prosthetic valve reopera- 
tion experience to identify the incremental risk 
factors for hospital mortality, length of hospital stay, 
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and the occurrence of nonfatal persistent neurologic 
deficit after prosthetic valve reoperation. With these 
risk factors identified, the next goal of the study was 
to present the data in the form of equations that 
could be used to estimate the patient-specific prob- 
ability of  outcomes, based on information available 
at the time reoperation was considered. 
Patients and methods 
Patients. In the combined experience of the Mayo 
Clinic (n = 997 reoperations; 1963 to August 1, 1991), the 
University of Alabama Medical Center and the Birming- 
ham Veterans Affairs Medical Center (n = 861 reopera- 
tions; 1975 to January 1, 1992), and St. Vincent Hospital 
and Medical Center and the Oregon Health Sciences 
University (n = 388 reoperations; 1965 to January 1, 
1991), 1984 consecutive patients underwent 2246 pros- 
thetic valve reoperations; 217 of these patients, therefore, 
had two or more valve reoperations in these institutions. 
(Unless stated otherwise, throughout this manuscript the 
n refers to the number of reoperations, not the number of 
patients, because each procedure was entered into the 
data set as an independent observation.) Included were all 
reoperations during which a previously placed aortic, 
mitral, or tricuspid valve prosthesis was replaced or re- 
paired; the latter included suture closure of a peripros- 
thetic leak, thrombectomy, or exchange of a prosthetic 
valve poppet (Appendix Table A-l). Operations that 
included one or more concomitant procedures, such as 
coronary artery bypass grafting, ascending aortic aneurys- 
mectomy, or left ventricular aneurysmectomy were in- 
cluded (Appendix Table A-2). Replacements of right- 
sided valve conduits were excluded. The patient group 
consisted of 1395 male and 851 female patients, their ages 
ranging from 1.5 to 88 years at the time of reoperation 
(mean age 52 -+ 16 years). The most common indications 
for reoperation were periprosthetic leakage without evi- 
dence of infection, degeneration of a bioprosthesis, and 
prosthetic valve endocarditis (Appendix Table A-3). Al- 
though the majority of patients had symptoms but were in 
hemodynamically stable condition and undergoing a first 
elective reoperation, the data set included such clinical 
extremes as prophylactic reoperations in symptom-free 
patients, valve reoperations for the second time or more, 
and reoperations in patients in cardiogenic shock. Impor- 
tant comorbidity existed at the time of 493 reoperations 
(Appendix Table A-4). The types of device in place before 
and after reoperation are shown in Appendix Table A-5, 
and the preoperative position of prosthetic valves is shown 
in Appendix Table A-6. 
OUtcome events. Death in the hospital (hospital mor- 
tality), nonfatal (in hospital) new persisting neurologic 
deficit, and length of stay in the hospital after reoperation 
among hospital survivors were the outcome vents. Hos- 
pital mortality was defined as death at any time during the 
hospitalization for the reoperation, regardless of the 
length of that stay. Nonfatal persisting neurologic deficit 
was defined as a new, postoperative r sidual neurologic 
functional impairment not completely resolved at the time 
of discharge alive from the hospital. 
Data. Definitions for a common set of relevant vari- 
ables were established collaboratively before data collec- 
tion. The information was assembled by extracting infor- 
mation from each patient's complete hospital record by a 
standardized review process. After this was completed, a 
number of records randomly selected from the entire 
group were re-reviewed by two or more reviewers, and this 
showed good consistency in interpretation and transfer of 
data from the hospital record to the study forms. 
The collected variables were studied for reasonable- 
ness, for example, by comparing hemodynamic status with 
New York Heart Association (NYHA) class; by compar- 
ing age, height, weight, and body surface area; by verifying 
outcome events; by cross-checking variables according 
to the recorded pre-reoperation versus post-reoperation 
valve position. The data sets were then submitted to the 
University of Alabama at Birmingham for creation of the 
database. In compliance with the patient confidentiality 
required by each of the three institutional review boards, 
the database contained only noninformative patient iden- 
tification. 
Analysis. Correlation between variables was assessed; 
clusters of correlated variables were identified, a° univari- 
able associations of discrete variables to outcome were 
determined by two-way contingency table, and associa- 
tions of continuous and ordinal variables to outcome were 
assessed by two-sample t tests and logistic analyses. Mul- 
tivariable logistic regression analysis was then performed 
for the outcome vents hospital death and nonfatal neu- 
rologic deficit11; and linear regression was used to analyze 
the log-log transformation f length of postoperative stay. 
The analyses were performed by nonautomated, irected 
techniques.a2, 13 
The variables entered into the analyses are listed in 
Appendix Table B-1. All are known or can be anticipated 
at the time of considering a prosthetic valve reoperation. 
Thus, for example, global myocardial ischemic time was 
not considered; had it been, along with other factors 
available only at the time of performing the reoperation, 
it would have been identified as a risk factor (P < 0.0001), 
although it would lack interpretability in the face of the 
large number of different methods of myocardial protec- 
tion that were used. Transformations of scale for contin- 
uous and ordinal variables were performed to choose the 
most appropriate mode of their numeric expression to 
match the assumptions of the logistic equation. ~4 A P 
value of 0.05, based on the likelihood ratio test, was 
required for a variable to be retained in the final parsi- 
moniously derived equation. 
In conjunction with the overall multivariable analytic 
process, multiple subanalyses were made, with the general 
purpose of determining whether the analysis of the data- 
base as a whole was justified, as well as to assess the 
likelihood of interactions between certain variables. Thus, 
for example, institutions were analyzed separately, as were 
the valve positions. The consistency of the results across 
subsets upported the use of the entire database for the 
analysis and the lack of need for interaction terms. Some 
risk factors emerged with particularly strong relationships 
with outcome, and there was concern that the subset of 
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patients with these risk factors might unduly influence the 
risk factor elationships found in the lower risk patients. 
Consequently, the experiences with reoperations in elec- 
tive, hemodynamically stable, noninfected patients were 
analyzed separately. Theconsistency ofpredictions within 
this subset with those from the overall equation reinforced 
further the use of the database as a whole. On the basis of 
these analyses, and the consideration of interaction terms 
for these various subsets, he parsimonious risk factor 
equation was formulated. Solving this equation results in 
an estimate of the probability of hospital mortality after 
reoperation, accompanied by a measure of uncertainty 
(confidence limits [CLs]). All CLs portrayed are 90% CLs; 
when these are nonoverlapping, the P value for the 
difference between the point estimates is nearly certain to 
be less than 0.05. 
Validation of the multivariable analyses. The directed 
nonautomated technique of performing the final multiva- 
riable analysis of hospital death was compared with an 
automated bootstrap resampling method to determine the 
selection frequency of the risk factors, a5This latter was 
performed by automatic stepwise variable selection on 
1000 data sets each consisting of the patients in 2246 
reoperations, selecting randomly and independently each 
member of the data set from the original database. Thus 
a given patient was allowed to enter a given data set more 
than one time, or not at all, depending on chance; in fact, 
the membership of each of the 1000 data sets was differ- 
ent. The result was that the variables appearing most 
commonly in the 1000 analyses were the variables that 
appeared in the final equation presented in this paper 
(Appendix Table B-2). Also, the median number of
variables retained in the automated analyses was 15, a 
similar and slightly larger number than appeared in the 
final equation used in the paper (a positive validation). 
Lacking an external database for validating the quanti- 
tative predictions from the equation, internal predictive 
validity was tested by numerous comparisons of the actual 
number of hospital deaths in stratified groups of patients 
with the number of deaths predicted for that specific 
group by summing the predicted probabilities of each of 
the individuals in the group, each obtained by a patient- 
specific solution of the multivariable analysis (Appendix 
Table B-3). Using a X 2 goodness of fit test and 1000 
bootstrap samples to determine its sampling distribution, 
the P values for the differences between actual and 
predicted were always 0.4 or larger. 16 
Results 
Hospital death. Two hundred forty-three hospi- 
tal deaths occurred among the 2246 reoperations 
(10.8%; CL 9.8% to 12.0%). Both the risk-unad- 
justed (P(x 2) = 0.3) and the risk-adjusted (P(logis- 
tic) = 0.9) differences in hospital mortality among 
the three institutions could have been due to chance 
alone (Appendix Table B-3). By univariable analy- 
sis, there was no significant improvement in hospital 
mortality over the time of this study (Appendix 
Table A-7) (P(logistie) = 0.23); however, risk-ad- 
justed mortality was found to be higher before 1970 
(P = 0.02) (Table I). Having no relevance to current 
estimate of hospital events, this variable was not 
incorporated into the predictive quation. 
Multivariable logistic regression analysis identi- 
fied twelve other incremental risk factors for hospi- 
tal mortality (Table I), all of which would be known 
preoperatively and which were incorporated into the 
predictive risk equation. Data pertaining to each of 
these variables, including their univariable P values, 
are presented in table form (Tables II and III) in 
this section. Similar data pertaining to clinically 
important variables that were not retained in the 
predictive quation are presented in the appendix 
(Appendix Tables A-1 through A-8). 
Patient incremental risk factors for hospital 
death. The patients' age and weight (inverse rela- 
tion) at the time of reoperation were risk-adjusted 
(Table I) and risk-unadjusted (Table II) correlates 
of hospital death. Neither body surface area nor 
height was retained in the multivariable analysis 
once weight was entered. No evidence was found 
that including children undergoing valve reopera- 
tions confounded the analysis (P = 0.5); thus the 
predictive equation is applicable to both children 
and adults. A higher unadjusted risk among female 
patients, 13.0% (CL 11.8% to 14.3%), compared 
with male patients, 9.5% (CL 8.6% to 10.3%), 
appeared to be related to their smaller size. 
The number of previous heart operations was a 
moderately strong risk factor for hospital mortality 
in both multivariable (Table I) and univariable 
(Table II) analyses. The number of previous heart 
operations was a stronger predictor of risk than 
number of previous valve reoperations, although the 
two variables were identical in most patients. Previ- 
ous coronary artery bypass grafting had been per- 
formed in 233 patients. The hospital mortality in this 
group, 12.9% (CL 10.6% to 15.6%), was not believ- 
ably different from that in the group without previ- 
ous coronary bypass, 10.6% (CL 9.9% to 11.4%), in 
either analysis. 
Variables that reflected poorer preoperative l ft 
ventricular function proved to be both risk-unad- 
justed and risk-adjusted strong correlates of hospital 
mortality, including NYHA functional class, hemody- 
namic instability, and the presence of tricuspid in- 
competence (as either a past or current diagnosis) 
(Tables I and II). Priority of the reoperation was a 
strong univariate predictor of hospital death but was 
not retained in the analysis, being subordinate to 
functional class and hemodynamic stability (Appen- 
dix Table A-8). 
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Table I. Multivariable risk factors for hospital death after reoperation on valve replacement devices (n = 2246; 
hospital deaths = 243) 
Logistic 
Incremental risk factors for hospital death coefficient +_ SD P value 
Demographic 
Age* (older) 
Weightt (lower) 
No. of previous heart operations (higher) 
NYHA class (I-V)~: (higher) 
Hemodynamic status¶ (poorer) 
Tricuspid incompetence (past or at reoperation) 
Prosthetic valve infection 
Renal failure 
Surgical variables 
Aortic and mitral replacement devices in place at 
end of reoperation 
Repair of ascending aortic aneurysm by composite 
graft technique 
Coronary artery bypass grafting 
Left ventricular aneurysmectomy 
Reoperation before 1970§ 
0.6427 -+ 0.127 <0.0001 
0.5270 + 0.158 0.0008 
0.3310 + 0.103 0.001 
0.5744 -+ 0.099 <0.0001 
0.5647 + 0.111 <0.0001 
0.8647 -+ 0.21 <0.0001 
1.151 -+ 0.196 <0.0001 
0.8859 -+ 0.35 0.01 
0.5088 -+ 0.166 0.002 
1.498 -+ 0.37 <0.0001 
0.6005 -+ 0.23 0.009 
1.993 -+ 0.71 0.005 
0.9420 -+ 0.40 0.02 
Intercept -6.444. NYHA, New York Heart Association; SD, standard eviation. 
* [Age (years)/50] 2 squared transform of continuous variable. 
t[70/Weight (kg)] inverse transform of continuous variable. 
:~Ordinal variable. 
¶0 = Stable; 1 = hemodynamically unstable; 4 = cardiogenic shock (square transform of ordinal variable). 
§Variable not used in prediction equation for current patients (see Appendix C). 
Hospital mortality varied according to the clinical 
indication for reoperation (Appendix Table A-3). 
Prophylactic reoperations were associated with a 
mortality of 1.0%, whereas reoperations for pros- 
thetic valve endocarditis (Tables I and II) and for 
valve thrombosis carried a high risk. However, with 
the exception of prosthetic valve endocarditis (de- 
fined as present at the time of reoperation and the 
indication for the procedure), the wide variation in 
risk with operative indication is accounted for by the 
coexistence of other risk factors incorporated into 
the multivariable analysis. 
Among numerous coexisting preoperative medi- 
cal conditions (Appendix Table A-4), renal failure 
proved to have both univariable (Table II) and 
multivariable (Table I) correlation with hospital 
mortality. 
Procedural incremental risk factors for hospital 
death. As stated earlier, global myocardial ischemie 
time was a strong predictor of hospital mortality 
(P < 0.0001) (Fig. 1), but it was not retained in the 
final multivariable analysis because of its uncertainty 
in the preoperative time frame. On the other hand, 
the need for concomitant repair of ascending aortic 
aneurysm by composite technique (but not with sim- 
ple interposition graft), left ventricular aneurysmec- 
tomy, or coronary artery bypass grafting can usually be 
anticipated. These variables were moderately strong 
predictors of hospital mortality in both univariable 
(Table III) and multivariable (Table I) analyses. 
The actual procedure performed on the prosthe- 
sis at the reoperation--repair versus replacement-- 
did not convincingly influence hospital mortality, 
although the prevalence of hospital deaths was 
appreciably lower after poppet replacement and 
after thrombectomy than after other procedures 
(Appendix Table A-l). Neither the type of prosthe- 
sis in place at reoperation nor the type of prosthesis 
implanted influenced hospital mortality (Appendix 
Table A-5). At reoperation, the highest risk was 
experienced by patients receiving amitral xenograft. 
However, this observed increased risk was ac- 
counted for by the presence of other risk factors, 
implying that such valves were selectively placed in 
patients with greater underlying risk and perhaps 
perceived less life expectancy. 
The location of the prosthetic valve pathology did 
influence hospital mortality, with prosthetic mitral 
valve reoperations having greater unadjusted mor- 
tality than those on a prosthetic aortic valve (Ap- 
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Table II. The risk-unadjusted (actual) relation of preoperative patient variables to the hospital mortality 
Hospital deaths 
P 
Patient variable n No. % CL (%) (logistic) 
Ag e at reoperation(yr) 
< 
18 63 7 11.1 5.6-20 
18 . . . . . . . .  40 435 39 9.0 6.9-11.6 
40 . . . . . . . .  50 381 29 7.6 5.6-10.3 
50 . . . . . . . .  60 545 59 10.8 8.7-13.3 
60 . . . . . . . .  70 573 66 11.5 9.4-14.0 
70 249 43 17.3 13.5-22 
Weight at reoperation (kg) 
< 
50 134 23 17.2 12.1-24 
50 . . . . . . . .  60 373 49 13.1 10.4-16.4 
60 . . . . . . . .  70 502 50 10.0 7.9-12.5 
70 . . . . . . . .  80 483 49 10.1 8.0-12.7 
80 . . . . . . . .  90 284 21 7.4 5.1-10.6 
90 167 10 6.0 3.4-10.1 
Unknown 303 41 13.5 10.5-17.3 
No. of previous heart operations 
1 1665 154 9.2 8.1-10.5 
2 441 63 14.3 11.7-17.4 
3 103 17 16.5 11.0-24 
4 28 7 25 12.8-42 
5 5 1 20 1.4-65 
Unknown 4 1 25 1.7-74 
NYHA class 
I 299 7 2.3 1.2-4.5 
II 563 32 5.7 4.2-7.6 
III 854 78 9.1 7.6-11.0 
IV 425 91 21 18.2-25 
V 38 28 74 59-85 
Unknown 67 7 10.4 5.2-19.1 
Hemodynamic status 
Stable 2098 188 9.0 8.0-10.1 
Unstable 85 26 31 23-40 
Shock 36 26 72 57-84 
Unknown 27 3 11.1 3.5-27 
Tricuspid incompetence (past or at reoperation) 
No 2035 198 9.7 8.7-10.9 
Yes 207 44 21 16.7-27 
Unknown 4 1 25 1.7-74 
Prosthetic vane infection 
No 1993 185 9.3 8.2-10.4 
Yes 243 58 24 19.5-29 
Unknown 10 0 0 0-28 
Renal failure 
No 2149 217 10.1 9.1-11.2 
Yes 57 19 33 23-45 
Unknown 40 7 17.5 8.9-31 
Total 2246 243 10.8 9.8-12.0 
0.0002 
0.0003 
<0.0001 
<0.0001 
<0.0001 
<0.0001" 
<0.0001" 
<0.0001" 
CL, confidence limits; NYHA, New York Heart Association. 
*P(x:). 
pendix Table A-5 and A-6). This difference, how- 
ever, was not identified after multivariate analysis, 
implying that the greater mortality in the mitral group 
was due to a higher prevalence of risk factors. Never- 
theless, the multivariate analysis did reveal that multi- 
ple valve disease, defined as aortic and mitral replace- 
ment devices in place at end of reoperation, was an 
incremental risk factor (Tables I and II!). 
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Table III. The risk-unadjusted relation of surgical variables to the hospital mortality 
Hospital deaths 
Surgical variable n No. % CL (%) P(X 2) 
Aortic and mitral replacement devices in 
place at end of procedure 
No 1733 167 9.6 
Yes 513 76 14.8 
Repair of ascending aortic aneurysm by 
composRe graft echnique 
No 2197 229 10.4 
Yes 49 14 29 
Coronary arterybypass grafting 
No 2050 211 10.3 
Yes 196 32 16.3 
Left ventricular aneurysmectomy 
No 2228 239 10.7 
Yes 10 4 40 
Unknown 8 0 0 
Reoperation before 1970 
No 2183 234 10.7 
Yes 63 9 14.3 
Total 2246 243 10.8 
8.5-10.9 
12.3-17.7 
0.0009 
9.4-11.6 ] <0.0001 
18.4-41.2 
9.2-11.5 ] 
12.2-21.4 
9.7-11.9 ] 
16.0-69 
0-34 
9.7-11.9 ] 
7.9-24 
9.8-12.0 
0.009 
0.003 
0.4 
CL, 90% confidence limits. 
Prediction equation for hospital mortality. The 
twelve preoperative incremental risk factors for 
hospital mortality listed in Table I were analyzed as 
described to generate the predictive equation. In 
Appendix Table C, the variables are presented in 
detail, with their transformations of scale, logistic 
coefficients, and varianee-covariance matrix, in a 
form suitable to program a small calculator or 
computer to generate a patient-specific numeric 
estimate of hospital mortality and its degree of 
uncertainty. If only a few variables are under con- 
sideration, the equation can be used to construct 
nomograms depicting the contributions of various 
factors in affecting hospital mortality (Figs. 2 and 3). 
Persisting new neurologic deficit at hospital dis- 
missal. Among the 2003 hospital survivors, 22 
(1.1%, CL 0.8% to 1.6%) had a persisting new 
neurologic deficit. A multivariable analysis looking 
for incremental risk factors for this event was un- 
successful because of the relatively small number of 
events. However, the risk of such an event did 
correlate with predicted hospital mortality as esti- 
mated by the risk equation (Table IV and Fig. 4). 
Length of hospital stay. The median interval 
between the reoperation and hospital discharge was 
10 days; the 25th and 75th percentiles were 8 and 14 
days, respectively, and the 10th and 90th were 7 and 
23 days (Fig. 5). 
The non-risk-adjusted ffect of preoperative NYH 
class on length of stay is shown in Fig. 6, and the 
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Fig. 1. The risk-adjusted relation between global myocar- 
dial ischemic time and NYHA functional class on pre- 
dicted hospital mortality after a first reoperation under 
stable conditions without endocarditis, concomitant risk 
factors, or additional surgical procedures. The depiction 
is a nomogram of a specific solution of the predictive 
multivariable risk equation (Appendix Table C). The 
dashed lines enclose the 90% CLs around the continuous 
point estimates. 
risk-adjusted effect, along with the risk-adjusted effect 
of age at reoperation, in Table V. Other risk factors 
increasing length of stay included an earlier era (ear- 
lier date of reoperation), a poor preoperative hemo- 
dynamic state, extensiveness of the valve disease, a 
more extensive procedure performed at reoperation, 
and one institution (Appendix Table D-l). 
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Fig. 2. The risk-adjusted relation between age at reop- 
eration and NYHA functional class on predicted hospital 
mortality after a first reoperation under the same condi- 
tions outlined in Fig. 1. The depiction is a nomogram of a 
specific solution of the predictive multivariable risk equa- 
tion (Appendix Table C). The depiction is as for Fig. 1. A, 
Single valve disease (aortic or mitral). B, Double valve 
disease (aortic and mitral). 
Discussion 
Nature of the risk factors surrounding reopera- 
tion on a prosthetic valve. This study confirms the 
experiences of others in identifying variables that 
are associated with incremental risk of hospital 
mortality after prosthetic valve reoperations. 2-9The 
impact of most of the risk factors identified in this 
study on reoperative death is largely intuitive, and 
similar observations have also been made for mor- 
tality after primary valve replacement. 17"21 Thus 
such factors as older age, higher NYHA class, 
decompensated hemodynamic status, extensiveness 
of valve disease, need for concomitant procedures, 
15 Mult i institutional Study of ,' 
Prosthetic Valve Reoperations (n = 2246) , 
PVE ," 
Age ," 
NO Yes " t 
- 30 0.8 \ 2.6 \ .- / 
40 1.0 \ 3.1 \ ." / - /  
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=~ 70 2.3 \ 6.9 ~ , - "  
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Age (Years) at Reoperation 
Fig. 3. The risk-adjusted relation between age at reop- 
eration and the presence of prosthetic valve endocarditis 
(PVE) on predicted hospital mortality after a first reop- 
eration on a single prosthetic valve in the current era in a 
70 kg, hemodynamically stable patient in NYHA class I. 
The depiction is a nomogram of a specific solution of the 
predictive rnultivariable risk equation (Appendix Table 
C). The depiction is as for Fig. 1. 
Table IV. The prevalence of persisting neurologic 
deficits at hospital dismissal in the 2003 patients 
leaving the hospital alive after a reoperation on a 
valve replacement device, according to the predicted 
hospital mortality of the patients. (For this, the 
predicted mortality for each of the 2003 patients was 
determined, using the equation in Table I, and the 
stratification was based on this.) 
Predicted hospital 
mortality (%) 
Persisting neurologic deficit 
at hospital dismissal 
< n No. % CL (%) 
2 289 1 0.3 0.02-1.8 
2 . . .  5 603 4 0.7 0.2-1.6 
5 . . .  10 531 6 1.1 0.5-2.3 
10. . .  20 391 6 1.5 0.7-3.1 
20 189 5 2.6 1.1-5.7 
Total 2003 22 1.1 0.8-1.6 
P(logistic) 0.004 
CL, 90% confidence limits. 
and presence of infection are consistently identified 
as contributors to greater operative risk. Because 
most patients in the study had aortic and/or mitral 
valve disease, the left ventricle can be considered to 
be the ventricle most likely impaired. Thus left 
ventricular dysfunction is probably responsible for 
preoperatively higher NYHA class, hemodynamic 
instability, and tricuspid insufficiency. This dysfunc- 
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Fig. 4. The relation between predicted probability of 
hospital mortality after reoperation on a prosthetic heart 
valve (as determined by the multivariable risk equation of 
Appendix Table C) and predicted probability of a nonfatal 
persistent postoperative neurologic event. The dashed 
lines enclose the 90% CLs around the continuous point 
estimates. 
tion is probably responsible for much of the mortal- 
ity that is associated with these reoperations, and 
the inference that mortality could be lessened by 
earlier reoperation before the onset of left ventric- 
ular decompensation would appear valid. 
The process of identifying pertinent risk factors 
results in some observations that are not clinically 
intuitive. For example, such variables as the location 
or type of malfunctioning valve, the procedure per- 
formed (repair or re-replacement), or the type of 
valve inserted proved to be of minimal predictive 
value once risk-adjusted estimates of mortality were 
made. This would indicate that other variables, such 
as technical factors involved with sternal reentry, 
myocardial preservation, and valve exposure, are of 
paramount importance in determining operative 
risk. The strong correlation between global myocar- 
dial ischemic time and hospital mortality would 
support his contention. 
A different set of risk factors (Appendix Table 
D-l) was found to correlate with length of hospital 
stay after reoperation, although there was consider- 
able overlap with the incremental risk factors asso- 
ciated with hospital mortality (Table I). Because the 
cost and resource use of these procedures are 
related to some extent o the duration of hospital- 
ization, the existence of extreme values for some of 
the risk factors for longer stay should be considered 
in the decision for or against reoperation i  equiv- 
ocal situations. 
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Fig. 5. Cumulative frequency distribution of the interval 
between reoperation and hospital dismissal. Time zero is 
the time of the reoperation. 
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Fig. 6. Cumulative frequency distribution of the interval 
between reoperation and hospital dismissal, stratified 
according to the preoperative NYHA functional class. 
Time zero is the time of the reoperation. 
Use of the predictive risk equation. It would have 
been desirable for hospital mortality to be accu- 
rately predicted by use of a small number of simple 
variables that would have permitted graphic repre- 
sentation of the entire equation. However, the con- 
dition of patients coming to reoperation, as evi- 
denced in this study, is sufficiently complex that 
prediction of risk requires consideration of at least a 
dozen factors, and these cannot be encompassed by 
simple nomograms. Thus we recommend that the 
equation (Appendix C) be solved for each patient, 
including the calculation of confidence limits to 
properly interpret the predictions. 
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Table V. Risk-adjusted predicted interval (days) from a first reoperation after mitral valve replacement to
hospital dismissal, in a basically uncomplicated patient (other than NYHA class), according to the age at 
reoperation and the preoperative NYHA functional class. The table is a digital nomogram of a specific solution 
of the multivariable quation in Appendix Table D-1 
Preoperative NYttA class 
I II III IV V Age at 
reoperation 
(yr) Days CL Days CL Days CL Days CL Days CL 
20 7 4-13 7 5-14 8 5-15 9 5-17 13 7-31 
30 7 4-13 7 5-14 8 5-15 9 5-17 13 7-30 
40 7 4-13 7 5-14 8 5-15 9 5-17 13 7-31 
50 7 5-14 8 5-14 8 5-16 9 5-18 14 7-32 
60 8 5-15 8 5-15 9 5-17 9 6-19 15 8-36 
70 8 5-16 9 5-17 9 6-19 10 6-21 17 8-41 
80 9 6-19 10 6-20 11 6-22 12 7-25 19 9-50 
CL, 90% confidence limits; NY/-/A, New York Heart Association. 
The equation may appear intimidating but, on 
examination, requires information concerning 
twelve variables readily accessible in all patients for 
whom reoperative valve surgery is contemplated. In 
most instances the majority of these variables will 
have a value of zero (no risk factor present), and this 
simplifies the computations. The actual mathemat- 
ics of the equation requires use of the natural 
exponential function and otherwise simple multipli- 
cations, additions, and subtractions, all within the 
scope of small programmable calculators. 
The prediction of the risk of hospital mortality has 
many potential applications. First, it should be ben- 
eficial in preoperative counseling for the patient and 
family. For example, prophylactic removal of a 
Bj6rk-Shiley 60 ° convexo-concave mitral prosthesis 
(Shiley, Inc., Irvine, Calif.) could be under consid- 
eration for a 55-year-old, 61 kg, otherwise well 
patient, with no comorbid conditions. What is the 
risk of hospital mortality at a contemplated first 
reoperation? Referring to Appendix 2, one would 
enter age 55 years, weight 61 kg, NYHA class I (1), 
stable hemodynamics (0), renal failure--no (0), 
double valve disease--no (0), tricuspid incompe- 
tence-no (0), prosthetic valve endocarditis--no 
(0), number of previous heart operations (1), as- 
cending aortic aneurysm--no (0), left ventricular 
aneurysm--no (0), and coronary revasculariza- 
tion--no (0). Solving the equation for the probabil- 
ity of hospital mortality ields 1.5%, with 90% CLs 
of 1.1% to 2.2%. As would be typical of such 
patients, most of the twelve variables in the equation 
equal 0, so that only age, weight, NYHA class, and 
number of previous operations are relevant o the 
calculations. 
In contrast, consider a 68-year-old patient with 
chronic heart failure (NYHA class III), with chronic 
renal failure, tricuspid incompetence, and important 
symptoms related to ischemic heart disease. The risk 
in such a patient of a first prosthetic valve reopera- 
tion directed to either the aortic or the mitral valve 
is 43% (90% CL 33% to 54%). Indeed, such calcu- 
lations may enter into considerations of medical 
resource use when calculated risks exceed a partic- 
ularly high value with reasonable confidence. 
Second, use of the equation should be helpful in 
recommending the appropriateness of bioprosthetic 
valve implantation and in the timing of reoperation 
in cases of progressive bioprosthetic valve failure. 
For example, the estimated hospital mortality of 
early bioprosthetic valve replacement in a patient 
now in NYHA class II can be compared with the 
estimated risk of the same operation at a future time 
in a more advanced functional class (Figs. 1 to 3). 
Finally, the ability to predict with reasonable 
certainty the risk of reoperation i a specific patient 
has direct application to consideration fprophylac- 
tic replacement of Bj6rk-Shiley convexo-concave 
prosthetic heart valves believed to be at a relatively 
high risk for outlet strut fracture. 22 Several analyses 
offer guidelines for consideration f prophylactic 
valve replacement, including estimates of linearized 
risk for structural valve failure, 23-25 but none pro- 
vides the other essential data required to assess the 
advisability of reoperation, amely, patient-specific 
risk of hospital mortality as provided by this study. 
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For example, Marrin, Birkmeyer, and O'Connor 25 
present nomograms for evaluating the benefit of 
prophylactic reoperation for individual patients with 
60-degree convexo-concave alves, the independent 
variables being the patient's age, linearized outlet 
strut fracture rate (known for any given valve), and 
estimated mortality of reoperation. Use of the pre- 
diction equation derived in this study permits more 
accurate patient-specific localization on the nomo- 
grams, resulting in credible recommendations re-
garding the advisability of elective reoperation. The 
analysis of this problem by Blackstone and Kirklin 1 
would have been further strengthened byavailability 
of such an equation. 
Strengths of the study. The three centers partic- 
ipating in the study represent mature valve replace- 
ment surgery teams whose combined prosthetic 
valve reoperation experience is more than 2000 
cases, permitting analysis of the entire spectrum of 
patients undergoing these operations. Although the 
referral nature of the three practices explains the 
substantial number of very ill patients coming to 
reoperation, a particular strength of the combined 
data set is the experience with the recall of Braun- 
wald-Cutter prostheses (Cutter Biological, Berkeley, 
Calif.); thus prophylactic valve reoperations consti- 
tuted about 10% of the cases, providing valuable 
data at the opposite clinical extreme. The collabo- 
rators included biostatisticians, epidemiologists, 
physicians, and surgeons with long experience in the 
field, focused on developing together a usable 
method for estimating patient-specific risk in future 
patients, firmly based on a rich set of data. 
Limitations of the study. The three participating 
centers may not be representative of many clinical 
practices in terms of patient selection, surgical ex- 
pertise, support services, and other variables. Thus 
the predicted results may not be obtained in all 
settings. The uniformity of results within these three 
institutions after adjustment for case mix (preva- 
lence of risk factors) argues that the data are not 
extreme and the results predicted should be obtain- 
able in comparable nvironments. 
The prediction equation was based on a specific 
data set, and its application to another entirely 
different group of patients (such as a series of future 
patients or those from another center) remains to be 
tested. In particular, its application to the dilemma 
facing younger patients harboring large-sized Bj6rk- 
Shiley convexo-concave mitral valve prostheses is 
predicated on the finding that valve position is not 
an incremental risk factor. This finding renders 
applicable the information from the elective xplan- 
ration of Braunwald-Cutter aortic valve prostheses, 
despite its being confined to the aortic rather than to 
the mitral valve position. 2'26 
Finally, the analysis is of hospital death, not 
time-related eath. The information on hospital 
mortality is of great interest o patients and their 
physicians, but "early" deaths after valve operations 
are not confined to the hospital. 27 
Inferences. The risk of prosthetic valve reopera- 
tions is highly variable. Knowledge of the average 
risk (in this study, 11%) is of limited value; pre- 
dicted mortality on the basis of the risk factors 
found in this study range from near zero to near 
100%. The risk of elective, and particularly of 
prophylactic, reoperations in otherwise well patients 
is low. If the risk of valve dysfunction is highest in 
young patients (as is true of xenografts and probably 
of the Bj6rk-Shiley convexo-concave prosthesis) and 
the risk of reoperation is low (3% or less), then 
consideration of elective and even prophylactic re- 
operations needs to be entertained. This study pro- 
vides a method for quantitating the risk in the form 
of a mathematical equation to facilitate these con- 
siderations. 
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Appendix Table A-I. The risk-unadjusted relation of the procedure performed at reoperation to the hospital 
mortality 
Procedure performed at
reoperation  valve replacement 
device 
Hospital deaths 
n No. % CL (%) 
Replacement of prosthesis 1888 209 11.1 9.9-12.3 
Suture repair of leak 256 27 10.5 7.6-14.3 
Poppet replacement 53 3 5.7 1.8-14.6 
Thrombectomy of prosthesis 19 1 5.3 0.4-24 
All others (including multivalve 30 3 10 3.1-25 
procedures) 
P(X a) 0.7 
Total 2246 243 10.8 9.8-12.0 
CL, 90% confidence limits. 
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Appendix Table A-2. The risk-unadjusted relation of concomitant procedures performed at reoperation to the 
hospital mortality 
Hospital deaths Unknown 
Concomitant procedure n No. % CL (%) n (deaths) 
Coronary artery bypass grafting 196 32 16.3 12.2-21 
Ascending aortic aneurysmectomy 73 16 22 14.5-32 
Composite graft technique 49 14 29 18.4-41 
Interposition graft 24 2 8.3 1.8-25 
Left ventricular aneurysmectomy 10 4 40 16.0-69 
Aortic root repair 149 21 14.1 9.8-19.8 
Repair of LV rupture 7 4 57 24-86 
LV outflow enlargement 20 4 20 7.7-41 
None of the above 1848 177 9.6 8.9-10.3 
0 (0) 
9 (0) 
(0) 
(0) 
8 (0) 
4 (0) 
9 (0) 
4 (0) 
2 (0) 
CL, 90% confidence limits; LV, leftventricular. 
Note: (1) Categories are not mutually exclusive. (2) Data about concomitant procedures other than those above were not collected. 
Appendix Table A-3. Indications for the 2246 reoperations on a valve replacement device 
Hospital deaths 
Indication for reoperation n No. % CL (%) 
Periprosthetic leakage without evidence of infection 
Degeneration of bioprosthesis 
Prosthetic valve endocarditis 
Structural failure of mechanical prosthesis 
Prophylactic device removal or repair 
Tissue ingrowth 
Patient-prosthesis mismatch 
Device thrombosis 
Multiple thromboemboli 
Hemolysis 
Concomitant cardiac surgery 
Structural failure of unspecified type prosthesis 
Anticoagulant intolerance 
Other (unspecified) 
Unknown 
600 64 10.7 8.7-13.0 
558 47 8.4 6.6-10.7 
243 58 24 19.5-29 
202 21 10.4 7.2-14.7 
193 2 1.0 0.2-3.5 
121 14 11.6 7.3-17.7 
100 10 10.0 5.7-16.6 
75 16 21 14.1-31 
70 5 7.1 3.0-14.8 
52 5 9.6 4.1-19.6 
43 7 16.3 8.2-28.8 
17 1 5.9 0.4-26 
8 0 0 0-34 
6 0 0 0-41 
10 0 0 0-28 
CL, 90% confidence limits. 
Note: (1) Categories are not mutually exclusive, b cause different indications could be specified for each prosthesis n place at the time of reoperation. 
(2) only 50 patients who had multiple valve r operations had two different indications f r reoperation. None had three indications. There were 21 different 
combinations of the above indications, with the largest group being 8.
Appendix Table A-4. The risk-unadjusted relation of coexisting morbid conditions at reoperation to the 
hospital mortality 
Coexisting morbid condition 
Hospital deaths Unknown 
n No. % CL (%) n (deaths) 
Cerebrovascular disease 225 25 11.1 7.9-15.3 61 (11) 
Previous myocardial infarction 134 26 19.4 14.1-26 44 (9) 
Chronic obstructive pulmonary disease 92 14 15.2 9.6-23 59 (11) 
Diabetes 84 14 16.7 10.6-25 63 (9)
Oral medication 36 7 19.4 9.9-34 57 (9) 
Insulin 48 7 14.6 7.3-26 61 (9) 
Renal failure 57 19 33 23-45 40 (7) 
None of the above 1753 156 8.9 7.8-10.1 12 (3) 
CL, 90% confidence limits. 
Note: (1) Categories are not mutually exclusive. (2) Data about coexisting medical conditions o her than those above were not collected. 
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Appendix Table A-5. The type of single valve replacement device in place before reoperation, the prevalence 
and mortality of repair of those devices, and the type of valve replacement device in placeafter the reoperation 
in those in whom the device was replaced. Among the patients with a single aortic replacement device in place, 
92 (17 hospital deaths) had also at reoperation a primary replacement of a mitral valve, along with replacement 
of the tricuspid valve in two others. Eighty-five (11 hospital deaths) of those with a single mitral replacement 
device in place preoperatively also underwent a first replacement of the aortic valve, and 14 (four hospital 
deaths) others had also replacement of the tricuspid valve, while four others (two hospital deaths) had also 
primary replacement of the aortic and tricuspid valves. Among the patients with a tricuspid valve in place, on  
(who survived) also had a first replacement of the aortic and mitral valves. 
Type of device 
Device in place before 
reoperation Repairs 
Device in place after 
reoperation if valve replaced 
Hospital deaths Hospital deaths Hospital deaths 
n No. % CL (%) n No. % CL (%) n No. % CL (%) 
Isolated aortic 
Aortic allograft 183 7 3.8 1.9-7.3 1 0 0 0-93 44 5 11.4 4.9-23 
Aortic xenograft 292 29 9.9 7.3-13.4 10 1 10 0.7-41 202 22 10.9 7.6-15.3 
Aortic mechanical 714 73 10 .2  8.4-12.3 132 10 7.6 4.3-12.7 819 70 8.5 7.0-10.4 
Aortic unknown type 24 1 4.2 0.3-19.6 2 0 0 0-75 3 2 0 0-93 
Isolated mitral 
Mitral allograft 1 0 0 0-93 0 0 
Mitral xenograft 249 30 12.0 8.9-16.1 20 4 20 7.7-41 133 23 17.3 12.2-24 
Mitral mechanical 393 44 11.2 8.7-14.2 108 7 6.5 3.2-12.1 392 43 11.0 8.5-14.0 
Mitral unknown type 16 3 18.8 5.9-42 1 0 0 0-93 5 0 0 0-47 
Isolated tricuspid 
Tricuspid xenograft 5 1 20 1.4-65 0 5 1 20 1.4-65 
Tricuspid mechanical 5 1 20 1.4-65 1 1 100 7-100 4 0 0 0-54 
More than one device in place 364 54 14.8 11.9-'18.3 
Total 2246 243 10.8 9.8-12.0 
CL, 90% confidence limits. 
Appendix Table A-6. The risk-unadjusted relation of the position of the valve prosthesis before reoperation to 
the hospital mortality 
Position of the valve prosthesis Hospital deaths 
before reoperation n No. % CL (%) 
One prosthesis 1882 189 10.0 8.9-11.3 
Aortic 1213 110 9.1 7.8-10.6 
Mitral 659 77 11.7 9.7-14.0 
Tricuspid 10 2 20 4.4-51 
Two prostheses 332 51 15.4 12.3-19.1 
Aortic and mitral 284 41 14.4 11.2-18.4 
Mitral and tricuspid 46 10 22 12.6-34 
Aortic and tricuspid 2 0 0 0-75 
Three prostheses 32 3 9.4 2.9-23 
Aortic and mitral and tricuspid 32 3 9.4 2.9-23 
P(X 2) for position (2 x 7 table) 0.02 
P(X 2) for 1, 2, or 3 prostheses 0.02 
P(logistic) for 1, 2, or 3 prostheses 0.03 
Total 2246 243 10.8 9.8-12.0 
CL, 90% confidence limits. 
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Appendix Table A-7. The risk-unadjusted relation between the era in which the valve reoperation was 
performed and the hospital mortality 
Date of reoperation 
(yr) Hospital deaths 
>- < n No. % CL (%) 
1965 2 0 0 O-75 
1965 . . . . . . . .  1970 61 9 14.8 8.2-25 
1970 . . . . . . . .  1975 155 16 10.3 6.7-15.4 
1975 . . . . . . . .  1980 720 52 7.2 5.7-9.1 
1980 . . . . . . . .  1985 536 82 15.3 12.8-18.1 
1985 . . . . . . . .  1990 575 63 11.0 8.9-13.4 
1990 197 21 10.7 7.3-15.1 
P(logistic) 0.2 
Total 2246 243 10.8 9.8-12.0 
CL, 90% confidence limits. 
Appendix Table A-8. The risk-unadjusted relation of the priority of reoperation on a valve replacement device 
to the hospital mortality 
Hospital deaths 
Priority of reoperation n No. % CL (%) 
Elective 2040 172 8.4 7.5-9.5 
Urgent 64 18 28 19.2-39 
Emergency 116 49 42 35-50 
Subtotal 2220 239 10.8 9.7-11.9 
P(logistic) <0.0001 
Unknown 26 4 15.4 5.9-32 
Total 2246 243 10.8 9.8-12.0 
CL, 90% confidence limits. 
Appendix Table B-1. Variables entered into the 
multivariable analyses 
Patient variables 
Demography. Age, gender, origin, height, weight, body 
surface area, body mass index, ratio of weight to height. 
Left ventricular function and secondary effects of the valve 
disease. NYHA class (I to IV, class V is a moribund 
condition), hemodynamic state (stable, hemodynamic in- 
stability, or cardiogenic shock), urgency of reoperation 
(elective, urgent, emergency reoperation), left atrial en- 
largement, left ventricular enlargement, ricuspid valve 
incompetence ( ither previously, for which a procedure 
was performed, or at the time of reoperation). 
Indication for reoperation. Prosthetic valve endocarditis, 
periprosthetic leakage without apparent infection, bio- 
prosthesis degeneration, mechanical prosthesis failure, 
prosthesis thrombosis, multiple systemic emboli, hemoly- 
sis, patient-prosthesis mismatch, anticoagulant intoler- 
ance, elective replacement during indicated valve replace- 
ment of another native valve. 
Previous heart surgery. Interval since last heart valve 
operation, number of previous valve reoperations, num- 
ber of previous heart operations, previous aortic valve 
replacement, previous mitral valve replacement, previous 
simultaneous aortic and mitral valve replacement, type of 
prosthesis in place at time of reoperation (allograft, 
heterograft, mechanical), size of prosthesis in place at the 
time of reoperation. 
Coexisting cardiac conditions. History of myocardial 
infarction, previous coronary artery bypass grafting, pre- 
vious percutaneous transluminal coronary angioplasty, 
history of native valve endocarditis, history of prosthetic 
valve endocarditis, interval between previous operation 
and reoperation for prosthetic valve endocarditis, cerebral 
vascular disease. 
Coexisting noncardiac conditions. Re al failure (chronic 
dialysis or admission creatinine >.2.5 mg/dl), diabetes (use 
of oral hypoglycemics or insulin), chronic pulmonary 
failure, aneurysm of the ascending aorta. 
Procedure variables (only those variables that would be 
part of the pre-reoperation plan were considered) 
Valve reoperation. Position of valve(s) (aortic, mitral 
tricuspid) on which reoperation (repair or replacement) 
was performed, type of prosthesis in place at the end of 
the reoperation (allograft, heterograft, mechanical), pros- 
thesis repair versus replacement. 
Concomitant procedures. Repair of ascending aortic aneu- 
rysm with simple interposition graft or with composite graft, 
coronary artery bypass grafting, left ventricular aneurysmec- 
tomy, left ventricular outflow tract reconstruction. 
Institutional experience variables. Date of reopera- 
tion, institution. 
4 4 Piehler et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
January 1995 
Appendix Table B-2. Frequency of appearance of variables in 1000 separate sampling analyses using 
automated stepwise multivariable logistic regression (see Patients and methods) 
Vaffab~ n %of lO00 
Patient variables 
Demographic 
Age 
Weight 
Body surface area 
Female 
Left ventricular function and secondary effects of valvular heart disease 
NYHA class 
Hemodynamic state* 
Components of hemodynamic state 
Surgical priority* 
Components of surgical priority 
Tricuspid valve incompetence 
Left atrial enlargement 
Left ventricular enlargement 
Indications for reoperation 
Prosthetic valve endocarditis 
Periprosthetic leakage without infection 
Prosthesis degeneration 
Prosthesis thrombosis 
Previous heart surgery 
Number of previous valve r operations 
Number of previous heart operations 
Previous aortic valve replacement 
Previous mitral valve replacement 
Previous aortic and mitral valve replacement 
Previous isolated aortic valve replacement 
Previous isolated mitral valve replacement 
Type of prosthesis in place before reoperation 
Aortic valve allograft 
Aortic valve mechanical device 
Mitral valve xenograft 
Coexisting and previous cardiac onditions 
Ischemic heart disease 
History of myocardial infarction 
History of native valve endocarditis 
History of prosthetic valve endocarditis 
History of native valve or prosthetic valve endocarditis 
Coexisting noncardiac onditions 
Renal failure 
Diabetes 
Cerebral vascular disease 
Chronic pulmonary failure 
Aneurysm of the ascending aorta 
Procedure variables 
Valvular reoperation 
Aortic prosthesis reoperation 
Aortic prosthesis repair 
Aortic prosthesis replacement 
Mitral prosthesis reoperation 
Mitral prosthesis repair 
Mitral prosthesis replacement 
Prostheses in place at end of reoperation 
Isolated aortic prosthesis 
Isolated mitral prosthesis 
Both aortic and mitral prostheses 
Concomitant procedures 
Coronary artery bypass grafting 
Left ventricular aneurysmectomy 
987 98.7 
698 69.8 
95 9.5 
295 29.5 
999 99.9 
644 64.4 
216 21.6 
208 20.8 
169 16.9 
976 97.6 
41 4.1 
190 19.0 
849 84.9 
51 5.1 
70 7.0 
111 11.1 
173 17.3 
632 63.2 
24 2.4 
80 8.0 
115 11.5 
57 5.7 
32 3.2 
243 24.3 
287 28.7 
79 7.9 
215 21.5 
223 22.3 
128 12.8 
195 19.5 
42 4.2 
639 63.9 
332 33.2 
104 10.4 
98 9.8 
125 12.5 
95 9.5 
0 0.0 
111 11.1 
42 4.2 
1 0.1 
452 45.2 
36 3.6 
59 5.9 
430 43.0 
543 54.3 
632 63.2 
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Appendix Table B-2. Cont'd 
Variable n % of 1000 
Enlargement of aortic root 314 31.4 
Composite grafting of ascending aortic aneurysm 785 78.5 
Institutional variables 
Center 
Mayo Clinic 36 3.6 
University of Alabama at Birmingham 59 5.9 
University of Oregon 44 4.4 
Date of reoperation 
Overall 294 29.4 
Pre-1970 395 39.5 
*Ordinal variable. 
Appendix Table B-3. Examples of internal validation of the logistic multivariable quation (Table I) in stratified 
subgroups of patients. The method used for the prediction of the number of hospital deaths in each specific group 
and the method used to compare actual and predicted hospital mortality are described in the section on Patients and 
methods. "Ideal" elective reoperation indicates that the patients were without prosthetic valve infection, stable, 
undergoing a first elective reoperation on a mechanical or heterografl (xenografi) valve, with no concomitant 
procedure. 
Hospital deaths 
Actual Predicted 
P 
VaHab~ n No. % CL (%) No. % CL (%) vane 
Priority of reoperation 
Elective 2040 172 8.4 7.5-9.5 177.9 8.7 8.4-9.0 0.7 
Urgent 64 18 28 19.2-39 16.1 25.2 21-30 0.6 
Emergency 116 49 42 35-50 45.7 39.4 35-44 0.6 
Unknown 26 4 
Position of valve prostheses before reoperation 
One prosthesis 
Aortic 1213 110 9.1 7.8-10.6 104.0 8.5 8.0-9.1 0.6 
Mitral 659 77 11 .7  9.7-14.0 79.4 12.1 11.2-13.0 0.8 
Tricuspid 10 2 20 4.4-51 2.0 19.8 10.4-33 0.99 
Two prostheses 
Aortic and mitral 284 41 14.4 11.2-18.4 42.6 15.0 13.7-16.4 0.8 
Mitral and tricuspid 46 10 22 12.6-34 9.1 19.7 16.2-24 0.7 
Aortic and tricuspid 2 0 0 0-75 0.2 9.8 5.8-13.7 0.6 
Three prostheses 
Aortic and mitral and tricuspid 32 3 9.4 2.9-23 5.7 17.9 14.5-13.5 0.5 
Surgical center 
Mayo Clinic 997 98 9.8 8.3-11.5 96.9 9.7 9.1-10.3 0.9 
University of Alabama 861 96 11.1 9.5-13.1 98.2 11.4 10.6-12.3 0.8 
University of Oregon 388 49 12.7 10.0-15.8 47.9 12.4 11.3-13.5 0.9 
Stable, noninfected patients undergoing elec- 
tive reoperation 
NYHA class 
I 270 6 2.2 1.0-4.5 5.2 1.9 1.8-2.1 0.7 
II 507 23 4.5 3.2-6.4 22.6 4.5 4.2-4.8 0.9 
III 779 67 8.6 7.0-10.5 67.9 8.7 8.4-9.1 0.9 
IV 245 38 15.5 11.9-19.9 42.6 17.4 16.3-18.5 0.6 
Unknown 32 2 
"Ideal" elective reoperations 
NYHA class 
I 150 2 1.3 0.3-4.4 2.6 1.8 1.7-1.9 0.7 
II 225 6 2.7 1.2-5.4 8.6 3.8 3.6-4.1 0.6 
III 306 23 7.5 5.3-10.6 23.9 7.8 7.4-8.2 0.8 
CL, 90% confidence fimits; NYHA, New York Heart Association. 
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Appendix C. Pseudocode for the estimation of 
patient-specific (risk-adjusted) hospital mortality 
after heart valve reoperation and its confidence 
limits 
Values for twelve pat ient characteristics and anticipated 
surgical variables are required to solve the risk factor 
equation for the probabil ity of hospital mortality and its 
degree of uncertainty. The following formal statements 
(computer pseudocode) provide the information required 
to write programmable calculator or computer software 
code to accomplish this. 
Definition of the names of variables 
Let the following variable names be defined: 
NYHA= 
HD2STATE = 
AGE2YRS = 
INVWGTKG = 
RENAL = 
DOUBLE = 
TV INCOMP = 
PVE = 
OPENNUMB = 
AAA= 
LVA = 
CABG = 
Patient's NYHA class in numerical 
terms, 1 through 5 (5 is shock) 
corresponding to clinical classes I, II, 
III, IV, and V. 
Patient's hemodynamic state at 
reoperation, coded as 0 = stable, 1 = 
hemodynamical ly unstable, 4 = 
cardiogenic shock (this is a squared 
transform of the ordinal relationship 
0, 1,2).  
[Patient's age (years)/50] 2 (this is a 
scaled squared transform). 
70/[patient's weight (kg)] (this is a 
scaled inverse transformation).  
Does patient have chronic renal 
failure or creatinine > 2.5 mg/dl (0 = 
no, 1 = yes)? 
Does patient have multiple valve 
disease at the time of reoperat ion 
such that either (a) both aortic and 
mitral valves have in the past been 
replaced or (b) it is anticipated that 
at the end of the reoperation, both 
mitral and aortic prostheses will be in 
place (0 = no, 1 = yes)? 
Does patient presently have, or has the 
patient had in the past, important 
tricuspid valve incompetence, requiring 
intervention (0 = no, 1 -- yes)? 
Does the patient have active 
prosthetic valve endocarditis at the 
t ime of reoperat ion (0 = no, 1 = 
yes)? 
The number  of previous open heart 
operations this pat ient has had in the 
past (1 for the anticipated first 
reoperat ion after a primary valve 
replacement, for example). 
Is repair of an ascending aortic 
aneurysm, using the composite graft 
technique, anticipated (0 = no, 1 = 
yes)? 
Is resection of a left ventricular 
aneurysm anticipated (0 = no, 1 = 
yes)? 
Is coronary artery bypass grafting 
anticipated (0 = no, i = yes)? 
For each patient being evaluated, values for each of the 
above-defined variables will be substituted for the variable 
names. For example, a patient in NYHA class II I  will have 
the number  3 substituted for the variable name NYHA 
wherever it appears in the following statements. 
Point estimate (the probability of hospital mortality) 
Calculate the estimate of hospital mortality in logit 
units: 
LOGIT  = -6.44434 + 0.57445 •NYHA + 0.56473. 
HD2STATE + 0.64274. AGE2YRS + 0.52704 •
INVWGTKG + 0.88591. RENAL + 0.50879 •
DOUBLE + 0.86470 •TVINCOMP + 1.15119. 
PVE + 0.33105"OPENNUMB + 1.49854" 
AAA + 1.99283. LVA+ 0.60047. CABG 
Transform the logit units into the estimated probabil ity of 
hospital death, using the logistic equation: 
P= 1/(1+ EXP[ -  LOGIT])  
where EXP  is the natural  exponential function. (P can be 
converted to percent by multiplying it by 100.) 
Confidence limits (interval) around the point estimate. 
Asymptotic, asymmetric confidence interval calculations 
require using the variance-covariance matrix that is gen- 
erated as part of the logistic regression analysis. In this 
pseudocode, the matrix calculations are presented in 
l inear expression form. Thus the variance components 
appear as squared terms multiplied by the square of a 
single risk factor while covariance components appear as 
risk factor pairs. The latter are multiplied by 2 because 
they appear twice in the matrix. 
Let: 
XSX = 0.19593 + 0.00987 NYHA 2 + 0.01228 • 
HD2STATE 2 + 0.01620. AGE2YRS 2 + 0.02495 • 
INVWGTKG 2 + 0.12093 • RENAL 2 + 0.02756 • 
DOUBLE 2 + 0 .04267-TVINCOMP 2 + 0.03822 • 
PVE 2 + 0.01069. OPENNUMB z + 0.13998-AAA 2 
+ 0.49826 • LVA z + 0.05291 • CABG z + 2 • 
{-0.02715 • NYHA + 0.00957 • HD2STATE - 
0.03013 • AGE2YRS - 0.03190 • INVWGTKG + 
0.00024. RENAL - 0.00602" DOUBLE - 0.00047 
• TVINCOMP - 0.01447. PVE - 0.01494. OPEN- 
NUMB - 0.02134 • AAA - 0.02469 • LVA - 
0.00370 • CABG} + 2 • NYHA • {-0.00544 • 
HD2STATE - 0.00017. AGE2YRS - 0.00011 • 
INVWGTKG - 0.00251 • RENAL - 0.00141 • 
DOUBLE-  0.00206 • TVINCOMP - 0.00125 • 
PVE - 0.00116" OPENNUMB + 0.00131. AAA + 
0.00408 • LVA - 0.00093 • CABG} + 2 • 
HD2STATE • {0.00098 • AGE2YRS + 0.00052 • 
INVWGTKG - 0.00115 • RENAL + 0.00149 • 
DOUBLE + 0.00286 • TVINCOMP + 0.00079 • 
PVE + 0.00108. OPENNUMB + 0.00119- AAA + 
0.00020- LVA + 0.00245 •CABG} + 2- AGE2YRS 
• {0.00324 •INVWGTKG - 0.00155 • RENAL + 
0.00064 • DOUBLE + 0.00079 • TVINCOMP + 
0.00436 •PVE + 0.00280 •OPENNUMB + 0.00395 
• AAA + 0.00141 • LVA - 0.00426- CABG} + 2 • 
INVWGTKG • {0.00143 • RENAL + 0.00114 • 
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DOUBLE - 0.00136 • TVINCOMP + 0.00192 • 
PVE - 0.00076. OPENNUMB + 0.00339. AAA + 
0.00165 • LVA + 0.00114 •CABG} + 2.  RENAL .  
{0.00294 •DOUBLE + 0.00214 • TVINCOMP - 
0.00094. PVE + 0.00068• OPENNUMB + 0.00608 
• AAA - 0.00766. LVA - 0.00034" CABG} + 2" 
DOUBLE • {-0.00163 •TVINCOMP + 0.00403 • 
PVE - 0.00123" OPENNUMB + 0.00370- AAA - 
0.00278 • LVA + 0.00295 • CABG} + 2 • TVIN- 
COMP.  {0.00471 • PVE - 0.00117. OPENNUMB 
+ 0.00540 • AAA + 0.00557 • LVA + 0.00454 • 
CABG} + 2 .  PVE .  {0.00037 •OPENNUMB - 
0.00569 • AAA - 0.00200 • LVA + 0.00225 • 
CABG} + 2 • OPENNUMB • {0.00001 • AAA + 
0.00279 • LVA + 0.00090 • CABG} + 2 • AAA • 
{0.00749" LVA + 0.00018" CABG} - 0.00912" 2" 
LVA.  CABG 
The asymptotic standard error of LOGIT is estimated by: 
SELOGIT=SQRT[XSX]  
where SQRT is the square root function. 
Calculation of the upper and lower confidence limits 
requires a confidence coefficient to be specified (designat- 
ed below as CONFC). For approximately 70% confidence 
limits equivalent to plus and minus one standard eviation 
of the point estimate P, the confidence coefficient is 1. For 
95% intervals (2 standard deviations) the confidence 
coefficient CONFC is approximately 2. For 90% intervals 
used in this paper, the confidence coefficient was 1.645. 
Let: 
CONFC=Conf idence coefficient 
Then the lower and upper limits of the confidence interval 
about LOGIT are estimated as: 
LCLOGIT = LO GIT - CONFC • SELOGIT 
UCLOGIT  = LOGIT + CONFC • SELOGIT 
These symmetric onfidence limits are transformed into 
asymmetric confidence limits about P by: 
LCP= 1 / ( I+EXP[ -LCLOGIT] )  
UCP= 1 / ( I+EXP[ -UCLOGIT] )  
Verification of code. The following values for variables 
may be used to test each portion of the calculator or 
computer code generated from the above information. 
Substitute into the variable names the following non- 
sensible ,~alues (chosen ot to be the characteristics of any 
patient, but rather to exercise very part of the equation 
simultaneously to check for errors): NYHA = 3, 
HD2STATE = 0.25, AGE2YRS = 1.0404, INVWGTKG 
= 1.07692, RENAL = 0.14, DOUBLE = 0.2, TVIN- 
COMP = 0.!3, PVE = 0.12, OPENNUMB = 1.5, AAA = 
0.11, LVA = 0.16, and CABG = 0.24. Choose CONFC = 
1.64485. With these values substituted into the equations 
(program), LOGIT = -1.74280, P = 0.14896, XSX = 
0.021510, SELOGIT = 0.14666, LCLOGIT = -1.98404, 
UCLOGIT  = -1.50156, LCP = 0.12089, and UCP = 
0.18219. 
Appendix continues on page 48. 
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Appendix Table D-1. Correlates of length of postoperative stay among hospital survivors, determined by 
multivariable linear regression analysis. The dependent variable was In[In(length of postoperative stay, days)]. 
Correlates Coefficient +_ SD P value 
Demographic 
Age* (older) 
Age (younger) 
Race other than white 
Left ventricular function and secondary conditions 
NYHA class (I-V)t (higher) 
Hemodynamic status (poorer) 
Extensiveness of valvular heart disease 
Previous double or triple valve replacement 
Previous cardiac surgery 
Number of previous heart operations (higher) 
Indication for reoperation 
Prosthetic valve infection 
Tissue ingrowth 
Patient-prosthesis mismatch 
Structural failure of mechanical prosthesis 
Coexisting morbid conditions 
Renal failure 
Diabetes 
Past prosthetic valve infection 
Current position of valve replacement 
Mitral valve replacement 
Tricuspid valve replacement 
Concomitant procedures 
Repair of ascending aortic aneurysm by composite graft technique 
Coronary artery b pass grafting 
Surgical experience 
Date of reoperation:~ (earlier) 
Institution 
One institution 
0.143 _+ 0.032 <0.0001 
-0.0036 + 0.00126 0.005 
0.040 + 0.0147 0.006 
0.0062 + 0.00089 <0.0001 
0.066 _+ 0.0187 0.0005 
0.031 _+ 0.0113 0.006 
0.027 _+ 0.0065 <0.0001 
0.24 _+ 0.0133 <0.0001 
0.062 _+ 0.0179 0.0005 
0.060 -+ 0.0188 0.002 
0.031 + 0.0140 0.03 
0.177 _+ 0.028 <0.0001 
0.060 _+ 0.020 0.003 
0.040 _+ 0.0159 0.01 
0.051 -+ 0.0085 <0.0001 
0.050 + 0.021 0.02 
0.101 _+ 0.028 0.0004 
0.042 _+ 0.0140 0.003 
-0.151 _+ 0.0118 <0.0001 
0.030 -+ 0.0080 0.0002 
Intercept 1.15. NYHA, New York Heart Association; SD, standard deviation. 
*[Age (years)/50] 2 squared transformation. 
"~Squared transformation. 
SLogarithmic transformation f years since January 1, 1963. 
